The global NET treatment market to touch valuation around USD 4.2 billion by 2026, this market is anticipated to grow with 10.1% CAGR during the forecast time period.
The market is driven by growing occurrence of cancer among patients is expected to drive neuroendocrine tumor treatment market growth across the global.
Growing extensiveness of carcinoid tumors is anticipated to drive the NET treatment market during the forthcoming years. Huge investment in clinical trials by numerous pharmaceutical businesses to develop new products is another parameters driving the NET treatment market development.
Such as, Novartis AG has the witnessed highest numeral of clinical trials followed by the company named Pfizer Inc. and Ipsen Pharma. Furthermore, technical advancements in therapies to treat neuroendocrine tumors are expected to drive the NET treatment market development over the coming years. Few of these comprise of targeted drug therapies, PET imaging with Ga labeled Somatostatin, and tyrosine kinase therapies. Such as, Lutathera by Novartis AG received FDA sanction for the first ever radionucleotide therapy.
Many of these businesses have undertaken policies, for instance, product launch, regional development, strategic partnership and distribution agreements, to reinforce their market position. Such as, Novartis AG declared to purchase all the ordinary shares from its subsidiary group Novartis Groupe France S.A. in January 2018.
Market By Product
Market By Site
Market By End-user
Market By Geography
Europe captured the market share more than 20.5% of the global market share during the forecast period. Greater extent of public funding in Europe’s healthcare system has backed to this development. Furthermore, occurrence of target populace base paired with government support to control cancer captures to significant development of this region. Such as, formation of bodies, for instance, the European Cancer Observatory, produced consciousness about cancer. Asia Pacific is anticipated to observer profitable development forthcoming due to helpful government initiatives and improving healthcare infrastructure. Furthermore, economic growths in countries, for instance, China and India, are anticipated to aid drive the market development. Enormous populace base with low per capita income in the region captures to high need for reasonable treatment options.
North America captures the major market share in 2018 accounting for over 34.6% of its share and is projected to continue its dominance during the forthcoming. Main parameter contributing to development of this region comprise government support for high purchasing power parity, quality healthcare, availability of reimbursement, and growing occurrence of cancers in Canada and U.S.
Market companies are concentrating on implementing new strategies for instance regional expansion, partnerships, mergers and acquisitions, new product launches, and distribution agreements to surge their revenue share. The major players associated with the BoehringerIngelheim International GmbH, AVEO Oncology, Hutchison MediPharma Limited, Novartis AG, IpsenPharma,Pfizer, Inc., and Progenics Pharmaceuticals.